AlphAIalphai — Financial news for AI agents
aol.comAUG 203 min read$VSTM

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

Original reporting
aol.com
Published Aug 20, 2026, 12:47 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Verastem (VSTM) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$VSTMBullishHigh
01

Why it matters

The earnings beat and new financing provide a catalyst for short‑term price appreciation, while ongoing clinical trials present longer‑term upside.

02

Market read

Earnings release is material for biotech investors; may trigger sector rotation toward royalty‑financed companies.

03

What to watch

Potential regulatory delays for VS‑7375 and reliance on a single commercial product could limit upside.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release today

Background

Verastem Oncology reported its Q2 2026 financial results, highlighting commercial launch revenue, a $75M royalty financing, and guidance extending cash runway into 2027.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

Q2 2026 earnings release with revenue of $40.1M, $75M royalty financing, and cash runway guidance into H2 2027.

Expected impact

Potential short‑term price rally as investors digest better‑than‑expected revenue and cash runway extension.

Evidence & confidence

Earnings beat on revenue, new nondilutive financing and clear guidance reduce near‑term execution risk.

Market effects

Sector

Biotech sector may see renewed interest in companies with royalty financing and early commercial launches.

Regional

U.S. biotech investors likely to re‑price similar-stage oncology firms.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Despite financing, the company remains loss‑making and cash burn is high; price may be over‑optimistic.

Key entities

  • Company
    Verastem Oncology

    Biotech firm developing VS‑7375 and low‑grade serous ovarian cancer franchise.

  • Investor
    Oberland Capital

    Provider of $75M nondilutive royalty financing.

  • Partner
    Secura Bio

    Milestone payer of $15M for COPIKTRA sales.

Read at source← All news

Related articles

AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min
AUG 6
$VSTMMed

Verastem, Inc. (VSTM): Results of Operations and Financial Condition

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating

SEC EDGAR 8-K6 min
JUL 21
$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

benzinga.com7 min
JUN 17
$VSTMMed

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) shares rose after updated RAMP 205 pancreatic cancer trial data. The company reported 86% overall survival at six months and 68% progression-free survival at six months; 83% of patients had tumor shrinkage at the recommended phase 2 P2D dose, with no new safety signals. The update also noted 90% metastatic at diagnosis and 9 patients still on treatment.

benzinga.com4 min
AUG 28
$OMed

Why I Keep Buying This Monthly Dividend Powerhouse

Realty Income (O) offers a 5.27% dividend yield, higher than the 4.45% Treasury rate, and has raised its dividend for 114 consecutive quarters. CEO Sumit Roy deployed $2.8B in Q1 at a 7.1% cash yield, raising full-year investment guidance to $9.5B. Ten directors bought 3,214 shares each in May 2026, signaling insider confidence. The company reported Q2 2026 AFFO per share of $1.09, up 3.8% YoY, with portfolio occupancy at 98.8%. Fitch Ratings assigned Realty Income a 'A' rating in August 2026.

aol.com3 min